Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

BELLUS Health Inc. (T:BLU)

Business Focus: N/A

Jun 28, 2023 10:57 am ET
Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health
LONDON, June 28, 2023 /CNW/ - GSK plc (LSE: GSK) (NYSE: GSK) and BELLUS Health Inc. (TSX: BLU) NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC), by way of a plan of arrangement in accordance with Section 192 of the Canada Business Corporations Act (the "Arrangement"). The Arrangement was approved by BELLUS' shareholders on 16 June 2023.
Jun 16, 2023 01:50 pm ET
BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU.TO) (“BELLUS” or the “Company”) today announced the positive outcome of the BELLUS shareholders (“Shareholders”) vote at this morning’s special meeting of the Shareholders (the “Special Meeting”) held in-person, approving the previously-announced statutory plan of arrangement under section 192 of the Canada Business Corporations Act (the “Arrangement”) pursuant to which 14934792 Canada Inc. (the “Purchaser”), a corporation existing under the laws of Canada and a wholly-owned subsidiary of GSK plc (NYSE:
May 16, 2023 05:01 pm ET
BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU.TO) (“BELLUS” or the “Company”) today announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding of a special meeting (the “Special Meeting”) of shareholders of BELLUS (“Shareholders”) on June 16, 2023. At the Special Meeting, Shareholders will be asked to consider and, if deemed advisable, to adopt a special resolution (the “Arrangement Resolution”) approving the previously-announced statutory plan of arrangement under section 192 of the Canada Business Cor
May 12, 2023 04:01 pm ET
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough (“RCC”), today reported its financial and operating results for the quarter ended March 31, 2023.
Apr 26, 2023 06:00 pm ET
BELLUS Health Announces Meeting Updates
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough (“RCC”), has announced the meeting and record dates for the special meeting of shareholders to be held in connection with the acquisition of the Company by GSK plc for US$2.0 billion pursuant to a plan of arrangement (the “Acquisition Meeting”). The Company will hold the Acqui
Apr 18, 2023 12:11 pm ET
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced that they have entered into an agreement under which GSK will acquire BELLUS, a Canada-based, late-stage biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC) for US$14.75 per share of common stock in cash representing an approximate total equity value of US$2.0 billion (£1.6 billion). The acquisition provides GSK access to camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treat
Apr 05, 2023 07:00 am ET
BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating Once-Daily Extended-Release Formulation of Camlipixant in Comparison to Twice-Daily Immediate Rel
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough (“RCC”), today announced positive data from its Phase 1 bioavailability equivalence study evaluating a once-daily Extended-Release (“ER”) formulation of camlipixant in comparison to a twice-daily Immediate Release (“IR”) formulation. Camlipixant is the Company’s twice-daily, oral P2X3 antagonist product
Mar 21, 2023 04:30 pm ET
BELLUS Health Reports Year 2022 Financial Results and Business Highlights
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough (“RCC”), today reported its financial and operating results for the year ended December 31, 2022.
Mar 01, 2023 07:00 am ET
BELLUS Health to Participate in the Cowen 43rd Annual Health Care Conference
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will participate in the Respiratory/Infections panel discussion at the Cowen 43rd Annual Health Care Conference, being held March 6 - 8, 2023 in Boston, MA.
Feb 08, 2023 04:01 pm ET
BELLUS Health to Present on the Patient Experience and the Burden of Refractory Chronic Cough at the American Academy of Allergy, Asthma & Immunology Annual Meeting
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that two abstracts describing the patient medical journey and the negative impact of RCC on quality of life will be presented at the upcoming American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, being held in San Antonio, Texas from February 24-27, 2023.
Nov 14, 2022 04:01 pm ET
BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitivity indications, today reported its financial and operating results for the third quarter ended September 30, 2022.
Nov 10, 2022 04:01 pm ET
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will be participating in two upcoming healthcare investor conferences.
Oct 10, 2022 07:00 am ET
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that an abstract reviewing clinical data from the Phase 2b SOOTHE trial will be presented at the upcoming CHEST Annual Meeting, being held in Nashville, Tennessee from October 16-19, 2022.
Sep 06, 2022 07:00 am ET
BELLUS Health to Present at the H.C. Wainwright Global Investment Conference
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company at the H.C. Wainwright Global Investment Conference.
Sep 02, 2022 05:15 pm ET
S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index and S&P/TSX 60 Index
TORONTO, Sept. 2, 2022 /CNW/ - As a result of the quarterly review, S&P Dow Jones Indices will make the following changes in the S&P/TSX Composite Index and S&P/TSX 60 Index prior to the open of trading on Monday, September 19, 2022:
Aug 22, 2022 07:00 am ET
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the European Respiratory Society International Congress 2022
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that three abstracts reviewing clinical data from the Phase 2b SOOTHE trial will be presented at the upcoming European Respiratory Society (“ERS”) International Congress 2022, being held in Barcelona, Spain from September 4-6, 2022.
Aug 10, 2022 04:30 pm ET
BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today reported its financial and operating results for the second quarter ending June 30, 2022.
Jul 18, 2022 01:38 pm ET
BELLUS Health Closes US$153 Million Public Offering of Common Shares in Canada and the United States
BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”) announced today that it has completed its previously-announced underwritten public offering in Canada and the United States (the “Offering”) of 16,540,541 common shares at a price to the public of US$9.25 per common share. The total gross proceeds to the Company were US$153 million, before deducting the underwriting commissions and any expenses related to the Offering. Bellus has also granted to the underwriters an option exercisable by the underwriters within 30 days of the date of the underwriting agreement
Jul 13, 2022 09:57 pm ET
BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States
In connection with its previously announced public offering of common shares in Canada and the United States (the “Offering”), BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU) today announced that it has entered into an underwriting agreement with Jefferies, Evercore ISI and RBC Capital Markets as joint book-running managers and LifeSci Capital as lead manager (collectively, the “Underwriters”), relating to the public offering of 16,540,541 common shares. The shares are being sold at a public offering price of US$9.25 per common share. Closing of the Offering is expe
Jul 13, 2022 04:01 pm ET
BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU), announced today the filing of a preliminary prospectus supplement (the “Supplement”) to its amended and restated short form base shelf prospectus dated December 14, 2021, amending and restating the short form base shelf prospectus dated December 23, 2020 (the “A&R Base Prospectus”) in connection with a proposed public offering of its common shares (the “Offering”). The Supplement was filed with each of the securities regulatory authorities in the provinces of Canada. The Supplement and accompanying A&R Base Prospectus
Jul 12, 2022 07:00 am ET
Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other cough hypersensitivity indications, today announced a positive End-of-Phase 2 (“EOP2”) meeting with the U.S. Food and Drug Administration (“FDA”) and the details of the CALM Phase 3 program for BLU-5937, a highly selective, second generation P2X3 antagonist product candidate, for the treatment of refractory chronic cough (“RCC”).
Jul 05, 2022 07:00 am ET
BELLUS Health to Participate in the William Blair Biotech Focus Conference
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will be participating in a fireside chat at the William Blair Biotech Focus Conference.
Jun 01, 2022 07:00 am ET
BELLUS Health to Participate in the Jefferies Healthcare Conference
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will be participating in a fireside chat at the Jefferies Healthcare Conference, being held in New York, NY from June 8-10, 2022.
May 11, 2022 04:50 pm ET
BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today reported its financial and operating results for the first quarter ending March 31, 2022.
May 02, 2022 07:00 am ET
BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of BLU-5937 at the ATS 2022 International Conference
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that three late-breaking abstracts reviewing clinical data from the Phase 2b SOOTHE trial will be presented at the upcoming American Thoracic Society (ATS) 2022 International Conference, being held in San Francisco, CA from May 13-18, 2022.
Apr 25, 2022 04:01 pm ET
BELLUS Health to Participate in Multiple Upcoming Investor Conferences
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that the Company’s management team will participate in multiple upcoming investor conferences.
Mar 01, 2022 07:00 am ET
BELLUS Health to Participate in the Cowen & Co. 42nd Annual Health Care Conference
Panel Details: Event: Cowen & Co. 42nd Annual Health Care Conference Title: Respiratory/Infections Panel Date/Time: Tuesday, March 8th, 2022 at 2:10 p.m. ET
Feb 23, 2022 04:01 pm ET
BELLUS Health Reports Year 2021 Financial Results and Business Highlights
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other cough hypersensitivity indications, today reported its financial and operating results for the year ending December 31, 2021.
Dec 17, 2021 09:30 am ET
BELLUS Health Closes US$200 Million Public Offering of Common Shares in Canada and the United States
BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”) announced today that it has completed its previously-announced underwritten public offering in Canada and the United States (the “Offering”) of 25,000,000 common shares at a price to the public of US$8.00 per common share. The total gross proceeds to the Company were US$200 million, before deducting the underwriting commissions and any expenses related to the Offering. Bellus has also granted to the underwriters an option exercisable by the underwriters within 30 days of the date of the underwriting agr
Dec 14, 2021 09:25 pm ET
BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States
In connection with its previously announced public offering of common shares in Canada and the United States (the “Offering”), BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU) today announced that it has entered into an underwriting agreement with a syndicate of underwriters comprising Jefferies, Evercore ISI and RBC Capital Markets as joint book-running managers, and including LifeSci Capital as lead manager and H.C. Wainwright & Co. and Bloom Burton as co-managers (collectively, the “Underwriters”), relating to the public offering of 25,000,000 common shares. The s
Dec 13, 2021 04:01 pm ET
BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU), announced today the filing of a preliminary prospectus supplement (the “Supplement”) to its short form base shelf prospectus dated December 23, 2020 (the “Base Prospectus”) in connection with a proposed public offering of its common shares of US$175 million (the “Offering”). The Supplement was filed with each of the securities regulatory authorities in the provinces of Canada. The Supplement and accompanying Base Prospectus were also filed with the U.S. Securities and Exchange Commission (the “SEC”) as part of a regis
Dec 13, 2021 09:18 am ET
IIROC Trade Resumption - BLU
TORONTO, Dec. 13, 2021 /CNW/ - Trading resumes in:
Dec 13, 2021 09:08 am ET
IIROC Trading Halt - BLU
TORONTO, Dec. 13, 2021 /CNW/ - The following issues have been halted by IIROC:
Dec 13, 2021 07:00 am ET
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today announced that the 50 mg and 200 mg BID doses of BLU-5937 in its Phase 2b SOOTHE trial for the treatment of RCC achieved statistical significance on the primary endpoint with 34% placebo-adjusted reduction in 24-hour cough frequency observed (p ≤ 0.005) at day 28. BLU-5937 was generally well-tolerated, with low rates of taste-related advers
Nov 10, 2021 04:30 pm ET
BELLUS Health Reports Third Quarter 2021 Financial Results and Business Highlights
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today reported its financial and operating results for the third quarter ending September 30, 2021.
Nov 10, 2021 07:00 am ET
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will participate in fireside chats at two upcoming healthcare investor conferences.
Nov 01, 2021 07:00 am ET
BELLUS Health Convenes Virtual Analyst Event to Discuss the Chronic Cough Landscape and its Selective P2X3 Antagonist BLU-5937
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today announced that it will convene a virtual analyst event to discuss the chronic cough landscape and its selective P2X3 antagonist, BLU-5937, on Monday, November 15, 2021 at 12:00 p.m. EST.
Sep 23, 2021 07:00 am ET
BELLUS Health Announces Completion of Patient Enrollment in SOOTHE Phase 2b Trial for Refractory Chronic Cough and BLUEPRINT Phase 2a Trial for Chronic Pruritus Associated with Atopic Dermatitis
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced that the Company has completed patient enrollment in the Phase 2b SOOTHE clinical trial of BLU-5937 in refractory chronic cough (“RCC”) and the Phase 2a BLUEPRINT clinical trial of BLU-5937 in chronic pruritus associated with atopic dermatitis (“AD”). Topline results from both trials are expected in December 2021.
Sep 13, 2021 07:45 am ET
BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced positive findings from a preplanned administrative interim analysis of the ongoing Phase 2b SOOTHE trial of BLU-5937, the Company’s highly selective P2X3 antagonist, in patients with refractory chronic cough (“RCC”).
Sep 02, 2021 07:00 am ET
BELLUS Health to Present at the H.C. Wainwright Global Investment Conference
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company at the H.C. Wainwright Global Investment Conference.
Aug 23, 2021 07:00 am ET
BELLUS Health to Report Additional RELIEF Data in an Oral Presentation at the European Respiratory Society International Congress 2021
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today announced that an abstract covering additional data from the RELIEF Phase 2a trial has been accepted for oral presentation at the upcoming European Respiratory Society (“ERS”) International Congress 2021, being held September 5-8, 2021.
Aug 11, 2021 04:30 pm ET
BELLUS Health Reports Second Quarter 2021 Financial Results and Business Highlights
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the second quarter ending June 30, 2021.
May 25, 2021 07:00 am ET
BELLUS Health to Participate in the Jefferies Virtual Healthcare Conference
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will be participating in a fireside chat at the Jefferies Virtual Healthcare Conference.
May 15, 2021 12:44 pm ET
Morganti & Co., P.L.C. Announces the Filing of a Securities Class Action on Behalf of Investors Who Acquired Bellus Health, Inc.
Morganti & Co., A pro-investor law firm with licensed and experienced lawyers in Canada and the United States that represent investors announces the filing of a securities class action on behalf of investors who purchased or otherwise acquired common stock of Bellus Health, Inc. ("Bellus" or "Company") (NASDAQ: BLU, TSX: BLU, FWB: BHN0) from September 5, 2019 through July 5, 2020, inclusive (the "Class Period").
May 12, 2021 07:00 am ET
BELLUS Health to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will be participating in a fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference.
May 10, 2021 04:30 pm ET
BELLUS Health Reports First Quarter 2021 Financial Results and Business Highlights
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the first quarter ending March 31, 2021.
May 10, 2021 07:00 am ET
BELLUS Health to Present at the American Thoracic Society 2021 International Conference
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today announced that three abstracts on BLU-5937 have been accepted for presentation at the upcoming American Thoracic Society ("ATS") 2021 International Conference, being held on May 14-19, 2021.
Apr 13, 2021 07:00 am ET
BELLUS Health to Present at the Bloom Burton & Co. Healthcare Investor Conference
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company at the Bloom Burton & Co. Healthcare Investor Conference.
Mar 24, 2021 07:00 am ET
BELLUS Health Appoints William Mezzanotte, MD, MPH to its Board of Directors
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced the appointment of William Mezzanotte, MD, MPH to its Board of Directors. Dr. Mezzanotte brings decades of vast development and commercial experience to the Board, including the development and approval of 30 products across multiple therapeutic areas.
Feb 25, 2021 04:01 pm ET
BELLUS Health Reports Year 2020 Financial Results and Business Highlights
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the year ending December 31, 2020.
Feb 22, 2021 07:00 am ET
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will participate in two upcoming virtual healthcare investor conferences.
Feb 18, 2021 12:08 pm ET
IIROC Trade Resumption - BLU
TORONTO, Feb. 18, 2021 /CNW/ - Trading resumes in:
Feb 18, 2021 11:59 am ET
IIROC Trading Halt - BLU
TORONTO, Feb. 18, 2021 /CNW/ - The following issues have been halted by IIROC:
Feb 18, 2021 10:43 am ET
IIROC Trade Resumption - BLU
TORONTO, Feb. 18, 2021 /CNW/ - Trading resumes in:
Feb 18, 2021 10:36 am ET
IIROC Trading Halt - BLU
TORONTO, Feb. 18, 2021 /CNW/ - The following issues have been halted by IIROC:
Jan 14, 2021 07:00 am ET
BELLUS Health to Present at the Eleventh International Virtual Cough Symposium
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced that Dr. Catherine Bonuccelli, M.D., BELLUS Health's Chief Medical Officer, and Dr. Denis Garceau, Ph.D., Bellus Health’s Senior Vice President of Drug Development, will be presenting data on BLU-5937 at the Eleventh International Virtual Cough Symposium being held on January 21-22, 2021.
Dec 23, 2020 04:51 pm ET
BELLUS Health Establishes At-the-Market Facility
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), announces that it has entered today into an agreement (the “Sales Agreement”) with Jefferies LLC ("Jefferies") pursuant to which the Company may from time to time in the future sell, through at-the-market distributions with Jefferies acting as sales agent, such common shares as would have an aggregate offer price of up to US$50.0 million, including sales made directly on the Nasdaq Global Market (“Nasdaq”) or on any other existing trading market for the common shares in the United States. No common shares will be offe
Dec 14, 2020 07:00 am ET
BELLUS Health Announces First Patient Dosed in its Phase 2 BLUEPRINT Trial of BLU-5937 for the Treatment of Chronic Pruritus Associated with Atopic Dermatitis
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that the first patient has been dosed in the Phase 2 BLUEPRINT trial of BLU-5937, the Company’s highly selective P2X3 antagonist, in patients with chronic pruritus associated with atopic dermatitis.
Dec 08, 2020 07:00 am ET
BELLUS Health Announces First Patient Dosed in its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that the first patient has been dosed in the Phase 2b SOOTHE trial of BLU-5937, the Company’s highly selective P2X3 antagonist, in patients with refractory chronic cough.
Dec 07, 2020 07:00 am ET
BELLUS Health Appoints Ramzi Benamar as Chief Financial Officer
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced the appointment of Ramzi Benamar to the role of Chief Financial Officer. Mr. Benamar is a seasoned financial executive, bringing over two decades of biopharmaceutical expertise to the position.
Nov 24, 2020 07:00 am ET
BELLUS Health to Participate in the Evercore ISI 3rd Annual Virtual HealthCONx Conference
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will participate in a fireside chat at the Evercore ISI 3rd Annual Virtual HealthCONx Conference.
Nov 12, 2020 07:00 am ET
BELLUS Health Reports Third Quarter 2020 Financial Results and Business Highlights
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the third quarter ended September 30, 2020.
Nov 10, 2020 07:00 am ET
BELLUS Health to Participate in Jefferies Virtual London Healthcare Conference
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference.
Oct 22, 2020 09:20 am ET
BELLUS Health Closes US$40 Million Public Offering of Common Shares in Canada and the United States, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it has completed its previously-announced underwritten public offering in Canada and the United States (the “Offering”) of 17,888,889 common shares at a price to the public of US$2.25 per common share, which includes the exercise in full of the underwriters’ option to purchase additional common shares. The total gross proceeds to the Company
Oct 19, 2020 11:25 pm ET
BELLUS Health Announces Pricing of US$35 Million Public Offering in Canada and the United States
In connection with its previously announced public offering of common shares in Canada and the United States (the “Offering”), BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU) today announced that it has entered into an underwriting agreement with a syndicate of underwriters comprising Jefferies and Evercore ISI as joint book-running managers, and LifeSci Capital as co-manager (collectively, the “Underwriters”), relating to the public offering of 15,555,556 common shares. The shares are being sold at a public offering price of US$2.25 per common share. Closing of the
Oct 19, 2020 04:15 pm ET
BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU), announced today the filing of a preliminary prospectus supplement (the “Supplement”) to its short form base shelf prospectus dated January 17, 2020 (the “Base Prospectus”) in connection with a proposed public offering of its common shares (the “Offering”). The Supplement was filed with each of the securities regulatory authorities in the provinces of Canada. The Supplement and accompanying Base Prospectus were also filed with the U.S. Securities and Exchange Commission (the “SEC”) as part of a registration statement o
Sep 08, 2020 07:00 am ET
BELLUS Health Announces Design for its Phase 2b Trial with BLU-5937 in Refractory Chronic Cough
BELLUS Health Inc. (NASDAQ:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced the planned trial design for SOOTHE, the Company’s Phase 2b dose confirmation trial evaluating the efficacy and safety of BLU-5937 in refractory chronic cough (RCC). The Phase 2b trial is designed based on the results from the Company’s previous Phase 2 RELIEF trial including the finding that baseline cough frequency is a key indicator of
Sep 03, 2020 07:00 am ET
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, President and Chief Executive Officer of BELLUS Health, will participate in two upcoming virtual healthcare investor conferences.
Aug 13, 2020 07:00 am ET
BELLUS Health Reports Second Quarter 2020 Financial Results and Business Highlights
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the second quarter ended June 30, 2020.
Jul 06, 2020 02:15 pm ET
IIROC Trade Resumption - BLU
TORONTO, July 6, 2020 /CNW/ - Trading resumes in:
Jul 06, 2020 02:09 pm ET
IIROC Trading Halt - BLU
TORONTO, July 6, 2020 /CNW/ - The following issues have been halted by IIROC:
Jul 06, 2020 01:35 pm ET
IIROC Trade Resumption - BLU
TORONTO, July 6, 2020 /CNW/ - Trading resumes in:
Jul 06, 2020 01:29 pm ET
IIROC Trading Halt - BLU
TORONTO, July 6, 2020 /CNW/ - The following issues have been halted by IIROC:
Jul 06, 2020 07:00 am ET
BELLUS Health Announces Topline Results from its Phase 2 RELIEF Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced topline results from its Phase 2 RELIEF trial of BLU-5937 in patients with refractory chronic cough.
May 28, 2020 07:00 am ET
BELLUS Health to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference.
May 14, 2020 05:00 pm ET
BELLUS Health Reports First Quarter 2020 Financial Results and Business Highlights, and Provides Updates on BLU-5937
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the first quarter ended March 31, 2020.
May 13, 2020 07:00 am ET
BELLUS Health Convenes Virtual KOL Meeting to Discuss the State of Chronic Cough Treatment and the BLU-5937 Program
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it will convene a virtual Key Opinion Leader (“KOL”) meeting to discuss the chronic cough landscape on Wednesday, May 27, 2020 at 9:00 a.m. EDT.
May 06, 2020 07:00 am ET
BELLUS Health to Present at the BofA Securities Virtual Health Care Conference
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company on Tuesday, May 12, 2020 at the BofA Securities Virtual Health Care Conference.
May 05, 2020 05:00 pm ET
BELLUS Health Announces Change to Annual and Special Shareholder Meeting Format
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced a format change to its upcoming annual and special meeting of shareholders (the “AGM”) being held on Thursday, May 14, 2020, at 2:30 p.m. ET.
Apr 06, 2020 05:00 pm ET
BELLUS Health Announces Completion of Dosing in Phase 2 RELIEF Trial with BLU-5937 for the Treatment of Refractory Chronic Cough
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (the “Company” or “BELLUS Health”) , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it has completed patient dosing in its Phase 2 RELIEF clinical trial of BLU-5937 for the treatment of refractory chronic cough, with 52 patients completing treatment. The Company decided to close the trial early due to the impact of the COVID-19 pandemic on the RELIEF clinical trial activities. The Company continues to expect topline data fr
Mar 25, 2020 02:07 pm ET
BELLUS Health Announces Closing of Transaction to Acquire Remaining Intellectual Property Rights to BLU-5937 from adMare BioInnovations
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (the “Company” or “BELLUS Health”) is pleased to announce that it has closed the transaction announced on March 23, 2020 (the “Transaction”) in accordance with the asset purchase and sale agreement entered into with adMare BioInnovations’ NEOMED Institute (“adMare”).
Mar 23, 2020 07:31 am ET
BELLUS Health Announces Transaction to Acquire Remaining Intellectual Property Rights to BLU-5937 from adMare BioInnovations
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (the “Company” or “BELLUS Health”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it has entered into an asset purchase and sale agreement to acquire all of the remaining BLU-5937 and related P2X3 antagonists intellectual property assets (the “BLU-5937 Assets”) from adMare BioInnovations’ NEOMED Institute (“adMare”) (the “Transaction”).
Mar 19, 2020 10:43 am ET
IIROC Trade Resumption - BLU
TORONTO, March 19, 2020 /CNW/ - Trading resumes in:
Mar 19, 2020 10:28 am ET
IIROC Trading Halt - BLU
TORONTO, March 19, 2020 /CNW/ - The following issues have been halted by IIROC:
Mar 19, 2020 07:00 am ET
BELLUS Health Announces Completion of Enrollment in Phase 2 RELIEF Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (the “Company” or “BELLUS Health”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it has completed patient enrollment for the RELIEF trial, its dose-escalation, placebo-controlled Phase 2 trial of BLU-5937 in patients with refractory chronic cough.
Feb 27, 2020 05:00 pm ET
BELLUS Health Reports Full Year 2019 Financial Results and Business Highlights on BLU-5937
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the year ended December 31, 2019.
Feb 20, 2020 07:00 am ET
BELLUS Health to Present at Two Upcoming Healthcare Investor Conferences
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, President and Chief Executive Officer of BELLUS Health, will participate in two upcoming healthcare investor conferences.
Nov 14, 2019 07:00 am ET
BELLUS Health Reports Financial and Operating Results for the Third Quarter Ended September 30, 2019
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the third quarter ended September 30, 2019.
Nov 13, 2019 07:00 am ET
BELLUS Health to Present at Jefferies Global Healthcare Conference in London
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company on Wednesday, November 20, 2019 at the Jefferies Global Healthcare Conference in London.
Sep 17, 2019 08:57 am ET
BELLUS Health Announces Exercise of Over-Allotment Option in Connection With Underwritten Public Offering of Common Shares
BELLUS Health Inc. (“BELLUS Health” or the “Company”) (Nasdaq: BLU; TSX: BLU), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that the underwriters of its previously announced underwritten public offering (the “Offering”) of common shares have partially exercised their option to purchase additional common shares, resulting in the issuance of an additional 1,320,296 common shares of the Company at a price of US$7.10 per common share for additional gross proceeds to the Co
Sep 09, 2019 09:09 am ET
BELLUS Health Closes US$70 Million Public Offering of Common Shares in Canada and the United States
BELLUS Health Inc. (“BELLUS Health” or the “Company”) (Nasdaq: BLU; TSX: BLU), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it has completed its previously-announced underwritten public offering in Canada and the United States (the “Offering”) of 9,859,155 common shares at a price to the public of US$7.10 per common share, for total gross proceeds of approximately US$70 million, before deducting the underwriting commissions and any expenses related to the Offering
Sep 05, 2019 07:00 am ET
BELLUS Health Announces Pricing of US$70 Million Public Offering in Canada and the United States
In connection with its previously announced public offering of common shares in Canada and the United States (the “Offering”), BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX: BLU) today announced that it has entered into an underwriting agreement with a syndicate of underwriters comprising Jefferies, Cowen and Guggenheim Securities, as joint book-running managers, Baird, as lead manager, and Bloom Burton Securities, as co-manager (collectively, the “Underwriters”). The Underwriters have agreed to purchase 9,859,155 common shares at a price of US$7.10 per common share (C$9.40 per co
Sep 03, 2019 08:05 am ET
BELLUS Health Announces the Launch of a US$60 Million Public Offering of Common Shares in Canada and the United States and the Filing of an Application to List Its Common Shares on Nasdaq
BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX: BLU), announced today the filing of a preliminary prospectus supplement (the “Supplement”) to its short form base shelf prospectus dated July 26, 2019 (the “Base Prospectus”) in connection with a proposed US$60 million public offering of its common shares (the “Offering”), and the filing of an application to list its common shares on the Nasdaq Global Market (“Nasdaq”) in the United States under the ticker “BLU”. Trading of the Company’s common shares is expected to commence on the Nasdaq following the pricing of the Offering. The Sup
Aug 26, 2019 07:00 am ET
BELLUS Health Strengthens Leadership Team with Appointment of Dr. Catherine Bonuccelli, MD as Chief Medical Officer
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced the appointment of Dr. Catherine Bonuccelli, MD to the role of Chief Medical Officer. Dr. Bonuccelli is a pediatric pulmonologist that brings over 20 years of pharmaceutical experience with significant expertise in clinical and product development of respiratory and non-respiratory products.
Aug 15, 2019 07:00 am ET
BELLUS Health Announces Share Consolidation
BELLUS Health Inc. (TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it is proceeding with a 3.6:1 consolidation of the Company’s common shares (the “Consolidation”) with an effective date of August 19, 2019. Notice has been provided to the Toronto Stock Exchange (the “TSX”) and BELLUS Health’s common shares are expected to begin trading on the TSX, on a consolidated basis, on or about August 19, 2019.
Aug 08, 2019 07:00 am ET
BELLUS Health Reports Financial and Operating Results for the Second Quarter Ended June 30, 2019
BELLUS Health Inc. (TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the second quarter ended June 30, 2019. All currency figures reported in this press release are in Canadian dollars, unless otherwise specified.
Jul 30, 2019 07:00 am ET
BELLUS Health Announces First Patient Enrolled in Phase 2 Study of BLU-5937 for the Treatment of Refractory Chronic Cough & Pursuit of Second Indication in Chronic Pruritus
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that the first patient has been enrolled in the RELIEF (A Randomized, Double-blind, Placebo-Controlled, Crossover, Dose Escalation Study of BLU-5937 in Subjects with Unexplained or Refract
Jul 15, 2019 07:00 am ET
BELLUS Health Convenes KOL Meeting to Discuss the State of Chronic Cough Treatment
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it will convene a Key Opinion Leader meeting to discuss chronic cough on Tuesday, July 16, 2019 in New York City. The event will include discussions on the unmet medical need in the category, and a review of current therapies in development including P2X3 antagonists. BELLUS Health will also provide clinical and regulatory updates on its lead P2X3 antagon
May 21, 2019 12:15 pm ET
BELLUS Health Presents Phase 1 Data for BLU-5937, its Lead Product Candidate for the Treatment of Refractory Chronic Cough, at the American Thoracic Society International Conference
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today presented results from the clinical Phase 1 study of BLU-5937, an orally-administered P2X3 antagonist, being developed for the treatment of refractory chronic cough. Clinical data presented at the American Thoracic Society International Conference in Dallas, Texas showed that BLU-5937 is well-tolerated and importantly, pr
May 15, 2019 07:00 am ET
BELLUS Health to Present at Three Upcoming Healthcare Investor Conferences
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, President and Chief Executive Officer of BELLUS Health, will present a corporate overview of the Company, including an update on its lead program BLU-5937 for the treatment of chronic cough, at three upcoming healthcare investor conferences.
May 08, 2019 05:00 pm ET
BELLUS Health Provides Update on Its Chronic Cough Drug Candidate BLU-5937 and Reports Financial and Operating Results for the First Quarter Ended March 31, 2019
BELLUS Health Inc. (TSX: BLU) (BELLUS Health or the Company), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today provided an update on BLU-5937, its lead drug candidate for refractory chronic cough, and reported its financial and operating results for the first quarter ended March 31, 2019. All currency figures reported in this press release are in Canadian dollars, unless otherwise specified.
Apr 04, 2019 07:00 am ET
BELLUS Health to Present at Two Upcoming Healthcare Investor Conferences
LAVAL, QC, April 4, 2019 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, President and Chief Executive Officer of BELLUS Health, will present a corporate overview of the Company, including an update on its lead program BLU-5937 for the treatment of chronic cough, at two upcoming healthcare investor conferences.
Apr 03, 2019 07:00 am ET
BELLUS Health Announces Clearance of U.S. IND for BLU-5937 Phase 2 Study in Chronic Cough Patients
- Phase 2 Study for Potential Best-in-Class Therapeutic for Refractory Chronic Cough Patients Expected to Start in Mid-2019 -
Feb 21, 2019 06:00 am ET
BELLUS Health Presents 2018 Highlights and 2019 Corporate Plan
- Reports Financial and Operating Results for the Year Ended December 31, 2018 -
Dec 28, 2018 07:00 am ET
BELLUS Health Announces Payment of $134,149 to Thallion CVR Holders
BELLUS Health Inc. (TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical needs, today announced that it will pay an amount of $134,149 to the...
Dec 18, 2018 08:53 am ET
BELLUS Health Closes $35M Financing to Support Development of its Lead Drug Candidate BLU-5937 for Chronic Cough
BELLUS Health Inc. (TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it has closed an equity offering, issuing a total of 36,842,105 common shares for gross proceeds of $35 million (the...
Dec 11, 2018 09:32 am ET
BELLUS Health Announces Pricing of $35 Million Public Offering of Common Shares
BELLUS Health Inc. (TSX: BLU) (BELLUS Health or the Company), a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical need, today announced the pricing of its overnight marketed equity...
Dec 11, 2018 09:02 am ET
IIROC Trade Resumption - BLU
TORONTO, Dec. 11, 2018 /CNW/ - Trading resumes in:
Dec 11, 2018 08:58 am ET
IIROC Trading Halt - BLU
TORONTO, Dec. 11, 2018 /CNW/ - The following issues have been halted by IIROC:
Dec 10, 2018 05:01 pm ET
BELLUS Health Announces Overnight Marketed Equity Offering
BELLUS Health Inc. (TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical need, today announced that it will undertake an overnight marketed...
Nov 19, 2018 04:00 pm ET
BELLUS Health Announces Positive Top-Line Phase 1 Results for its Chronic Cough Drug Candidate BLU-5937
BELLUS Health Inc. (TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical need, today announced positive top-line results from the clinical Phase...
Nov 14, 2018 04:00 pm ET
BELLUS Health Updates BLU-5937 Top-Line Phase 1 Results Timeline to November 2018
- Reports Financial and Operating Results for the Third Quarter Ended September 30, 2018 -
Sep 25, 2018 07:00 am ET
BELLUS Health Announces Appointment of Clinical Advisory Board
-Team of Internationally-Renowned Cough Experts to Guide BLU-5937 Clinical Development Strategy-
Aug 30, 2018 07:00 am ET
BELLUS Health to Present at Baird 2018 Global Healthcare Conference
LAVAL, QC, Aug. 30, 2018 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical need, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company, including its lead program BLU-5937 for the treatment of chronic cough, on Thursday September 6, 2018 at 2:00 pm ET at the Baird 2018 Global Healthcare Conference in New York.
Aug 08, 2018 07:00 am ET
BELLUS Health Reports Financial and Operating Results for the Second Quarter Ended June 30, 2018
- Data from Ongoing Phase 1 Study for Lead Drug Candidate BLU-5937 Expected in Q4 2018 -
Jul 19, 2018 07:00 am ET
BELLUS Health Announces Patent Protection Secured in All Major Pharmaceutical Markets for Lead Drug Candidate BLU-5937
- Grant of Japanese Patent Expands Portfolio That Also Includes United States, Europe and China -
Jul 09, 2018 07:30 am ET
Jul 09, 2018 07:30 am ET
Jun 27, 2018 11:30 am ET
BELLUS Health Presents BLU-5937 Preclinical Data and Updated Phase 1 Timeline at 2018 International Cough Symposium
- Preclinical Data Highlights BLU-5937 as a Potential Best-In-Class Treatment for Chronic Cough -- First In-Human Study to Begin in July 2018 - 
Jun 20, 2018 07:00 am ET
BELLUS Health to Present at the 2018 International Cough Symposium
LAVAL, QC, June 20, 2018 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today announced that Dr. Denis Garceau, BELLUS Health's Senior Vice President, Drug Development, will present the Company's lead drug candidate for the treatment of chronic cough, BLU-5937, at the 2018 International Cough Symposium in London, UK, on Wednesday June 27, 2018 at 4:30 pm BST (11:30 am EDT).
May 15, 2018 04:21 pm ET
BELLUS Health Reports Financial and Operating Results for the First Quarter Ended March 31, 2018
- Completed studies required to submit clinical trial application for BLU-5937 for chronic cough -- Announces voting results from Annual Meeting -
Apr 30, 2018 02:27 pm ET
BELLUS Health Responds to Recent Share Price Appreciation and Increased Trading Activity
LAVAL, QC, April 30, 2018 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today responded to a request from the Investment Industry Regulatory Organization of Canada (IIROC) to comment on recent trading activity of BELLUS Health's shares.
Apr 26, 2018 07:00 am ET
BELLUS Health to Present at Bloom Burton & Co. Healthcare Investor Conference
LAVAL, QC, April 26, 2018 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company, including an update on its lead program, BLU-5937 for the treatment of chronic cough, on Thursday May 3, 2018 at 9:30 am ET at the 2018 Bloom Burton & Co. Healthcare Investor Conference.
Feb 21, 2018 06:00 am ET
BELLUS Health Reports Financial and Operating Results for the Year Ended December 31, 2017
LAVAL, QC, Feb. 21, 2018 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today reported its financial and operating results for the year ended December 31, 2017. All currency figures reported in this press release are in Canadian dollars, unless otherwise specified.
Jan 09, 2018 06:00 am ET
BELLUS Health Receives Milestone Payment from Taro Pharmaceuticals
LAVAL, QC, Jan. 9, 2018 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today announced that it has received from Taro Pharmaceuticals Inc. ("Taro") a milestone payment of $400,000 in relation to the sale of its wholly-owned subsidiary Thallion Pharmaceuticals Inc. ("Thallion") in March 2017.
Jan 04, 2018 06:00 am ET
BELLUS Health to Present at Biotech Showcase™ 2018 Conference
LAVAL, QC, Jan. 4, 2018 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will provide a corporate overview of the Company, including BLU-5937, its lead program for chronic cough, at the upcoming Biotech Showcase™ 2018 Conference on Tuesday, January 9 at 9:30 am PT (12:30 pm ET) in San Francisco, CA, at the Hilton San Francisco Union Square.
Dec 12, 2017 07:29 am ET
BELLUS Health Closes $20M Common Share Financing
- Proceeds to Support Advancing BLU-5937 for Chronic Cough into Clinical Testing -
Dec 05, 2017 09:27 am ET
IIROC Trade Resumption - BELLUS Health Inc.
Toronto, Ontario--(Newsfile Corp. - December 5, 2017) - Trading resumes in:
Dec 05, 2017 09:25 am ET
IIROC Trade Halt - BELLUS Health Inc.
Toronto, Ontario--(Newsfile Corp. - December 5, 2017) - The following issues have been halted by IIROC:
Nov 08, 2017 07:00 am ET
BELLUS Health Reports Financial and Operating Results for the Third Quarter Ended September 30, 2017
LAVAL, QC, Nov. 8, 2017 /CNW/ - BELLUS Health Inc. (TSX: BLU) (BELLUS Health or the Company), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today reported its financial and operating results for the third quarter ended September 30, 2017. All currency figures reported in this press release are in Canadian dollars, unless otherwise specified.
Sep 27, 2017 08:00 am ET
BELLUS Health Appoints Dr. Clarissa Desjardins to its Board of Directors
LAVAL, QC, Sept. 27, 2017 /CNW/ - BELLUS Health Inc. (TSX: BLU) (BELLUS Health or the Company), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today announced that biotech entrepreneur Dr. Clarissa Desjardins is joining its Board of Directors.
Sep 20, 2017 08:00 am ET
BELLUS Health Chronic Cough Webcast Taking Place Today
- BELLUS to provide BLU-5937 program update, Key Opinion Leader Dr. Jacky Smith to present on chronic cough -
Sep 18, 2017 08:00 am ET
BELLUS Health's Blu-5937 Significantly Reduces Cough Without Taste Disturbance in Two Preclinical Models
- BELLUS to provide BLU-5937 program update during September 20th webcast -- Key Opinion Leader Dr. Jacky Smith to present on chronic cough -
Sep 06, 2017 08:00 am ET
BELLUS Health to host webcast on chronic cough and treatment approach on September 20, 2017
- Key Opinion Leader Dr. Jacky Smith to present on chronic cough -- Company will also present an update on BLU-5937, a novel drug candidate for chronic cough -
Aug 09, 2017 08:00 am ET
BELLUS Health Reports Financial and Operating Results for the Second Quarter Ended June 30, 2017
- Proceeds Received from Equity Sale Extend Cash Runway to 2019 -
Jun 19, 2017 08:00 am ET
May 09, 2017 06:00 pm ET
Apr 27, 2017 09:00 am ET
BELLUS Health to present at Bloom Burton & Co. Healthcare Investor Conference
LAVAL, QC, April 27, 2017 /CNW/ - BELLUS Health Inc. (TSX: BLU) (BELLUS Health or the Company), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company, including the recently in-licensed BLU-5937 program for chronic cough, on Monday May 1, 2017 at 11:30 am Eastern Time at the 2017 Bloom Burton & Co. Healthcare Investor Conference which will be held at the Sheraton Centre Toronto Hotel.
Apr 24, 2017 09:00 am ET
BELLUS Health Announces Grant of New U.S. Patent Covering Lead Compound for Chronic Cough
- Composition of Matter Patent with Expiration Date in 2034 -
Mar 16, 2017 06:00 pm ET
Feb 28, 2017 11:07 am ET
IIROC Trade Resumption - BLU
TORONTO, Feb. 28, 2017 /CNW/ - Trading resumes in:
Feb 28, 2017 10:54 am ET
Bellus Health Reports Financial and Operating Results for the Year Ended December 31, 2016
LAVAL, QC, Feb. 28, 2017 /CNW/ - BELLUS Health Inc. (TSX: BLU) (BELLUS Health or the Company), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today reported its financial and operating results for the year ended December 31, 2016. All currency figures reported in this press release are in Canadian dollars, unless otherwise specified.
Feb 28, 2017 10:52 am ET
BELLUS Health and The NEOMED Institute Announce an Exclusive Worldwide License Agreement for the Development of a Treatment for Chronic Cough
- Potential best-in-class drug candidate targetingthe clinically validated P2X3 receptor for chronic cough -- Potential to help millions of chronic cough patients,including those who do not respond to current therapies -
Feb 28, 2017 10:47 am ET
IIROC Trading Halt - BLU
TORONTO, Feb. 28, 2017 /CNW/ - The following issues have been halted by IIROC:
Feb 17, 2017 05:00 pm ET
Bellus Health Announces Payment to Thallion CVR Holders
The Company received funds in relation to the 2009 Thallion transaction and a payment of $577,152 will be made to the CVR holders on March 10, 2017
Dec 21, 2016 07:00 am ET
BELLUS Health provides update on pipeline
LAVAL, QC, Dec. 21, 2016 /CNW/ - BELLUS Health Inc. (TSX: BLU) (BELLUS Health or the Company), a drug development company focused on rare diseases, is providing an update on the projects in its pipeline.
Nov 10, 2016 07:00 am ET
BELLUS Health reports financial and operating results for the third quarter ended September 30, 2016
LAVAL, QC, Nov. 10, 2016 /CNW/ - BELLUS Health Inc. (TSX: BLU) (BELLUS Health or the Company), a drug development company focused on rare diseases, today reported its financial and operating results for the third quarter ended September 30, 2016. All currency figures reported in this press release are in Canadian dollars, unless otherwise specified.
Aug 09, 2016 08:00 am ET
BELLUS Health Provides Update on Project Pipeline and Reports Financial and Operating Results for the Second Quarter Ended June 30, 2016
LAVAL, QC, Aug. 9, 2016 /CNW/ - BELLUS Health Inc. (TSX: BLU) (BELLUS Health or the Company), a drug development company focused on rare diseases, today reported its financial and operating results for the second quarter ended June 30, 2016. All currency figures reported in this press release are in Canadian dollars, unless otherwise specified.
Jun 20, 2016 09:00 am ET
BELLUS Health announces top-line Phase 3 results of KIACTA™ for the treatment of AA amyloidosis
LAVAL, QC, June 20, 2016 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a drug development company focused on rare diseases, today announced top-line results from the Phase 3 study of KIACTA™ (eprodisate) for the treatment of AA amyloidosis.
Jun 02, 2016 08:00 am ET
BELLUS Health and Pharmascience announce scheduled conversion of Pharmascience's interest in BHI Limited Partnership
- Issuance of 6,350,638 common shares of BELLUS Health to Pharmascience upon conversion -
May 12, 2016 06:00 pm ET
BELLUS Health reports financial and operating results for the first quarter ended March 31, 2016
- Company also announces voting results from Annual Meeting of Shareholders -
Apr 26, 2016 08:00 am ET
BELLUS Health to present at Bloom Burton & Co. Healthcare Investor Conference
LAVAL, QC, April 26, 2016 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or "the Company"), a drug development company focused on rare diseases, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present an update on the Company's progress at the 2016 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Toronto Hotel on Monday May 2, 2016 at 10:30 am Eastern Time.
Feb 24, 2016 07:00 am ET
Bellus Health Reports Financial and Operating Results for the Year Ended December 31, 2015
LAVAL, QC, Feb. 24, 2016 /CNW/ - BELLUS Health Inc. (TSX: BLU) (BELLUS Health or the Company), a drug development company focused on rare diseases, today reported its financial and operating results for the year ended December 31, 2015.